INI 4001
Alternative Names: INI-4001Latest Information Update: 26 Jul 2024
At a glance
- Originator Inimmune
- Class Antineoplastics; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 24 Jul 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by Inimmune Corporation
- 29 Mar 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Australia (IV) (NCT06302426)
- 29 Mar 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Australia (IV) (NCT06302426)